Categories
All News

Targeted Drugs for NSCLC Market Overview, Top Companies, Region, Application and Global Forecast by 2026| Allergan, Amgen, ARIAD Pharmaceuticals (Takeda)

Targeted Drugs for NSCLC

The global Targeted Drugs for NSCLC market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Targeted Drugs for NSCLC market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Targeted Drugs for NSCLC market. The authors of the report profile leading companies of the global Targeted Drugs for NSCLC market, such as Allergan, Amgen, ARIAD Pharmaceuticals (Takeda), Beacon Pharma Limited, BeiGene, Biocon, Boehringer-Ingelheim, Celgene Corporation, Drug International Limted, Fujifilm Kyowa Kirin Biologics, Genvio Pharma Limited, Hetero Drugs, ImClone Systems ‎(Eli Lilly), Incepta Pharmaceuticals, Mylan, Novartis, Pfizer, Reliance Lifesciences, Roche, AstraZeneca, Cipla, Teva, OSI Pharmaceuticals, Glenmark Pharmaceuticals, Natco Pharma They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Targeted Drugs for NSCLC market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Targeted Drugs for NSCLC market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Targeted Drugs for NSCLC market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Targeted Drugs for NSCLC industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Targeted Drugs for NSCLC market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:  https://www.qyresearch.com/sample-form/form/2300351/global-targeted-drugs-for-nsclc-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Targeted Drugs for NSCLC market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Targeted Drugs for NSCLC market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Targeted Drugs for NSCLC market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Targeted Drugs for NSCLC Market by Product: Target EGFR, Target ALK, Target HER2, Target ROS1, Target BRAF, Target MEK, Target VEGFR2, Target VEGF, Target MET

Global Targeted Drugs for NSCLC Market by Application: , Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC

The report also focuses on the geographical analysis of the global Targeted Drugs for NSCLC market, where important regions and countries are studied in great detail.

Global Targeted Drugs for NSCLC Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report: https://www.qyresearch.com/customize-request/form/2300351/global-targeted-drugs-for-nsclc-market

Key questions answered in the report:

  • What is the growth potential of the Targeted Drugs for NSCLC market?
  • Which product segment will grab a lion’s share?
  • Which regional market will emerge as a frontrunner in the coming years?
  • Which application segment will grow at a robust rate?
  • What are the growth opportunities that may emerge in the Targeted Drugs for NSCLC industry in the years to come?
  • What are the key challenges that the global Targeted Drugs for NSCLC market may face in the future?
  • Which are the leading companies in the global Targeted Drugs for NSCLC market?
  • Which are the key trends positively impacting the market growth?
  • Which are the growth strategies considered by the players to sustain hold in the global Targeted Drugs for NSCLC market?

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/df096250a3267d700cf86dd389a9dbcf,0,1,global-targeted-drugs-for-nsclc-market

Table Of Contents:

1 Market Overview of Targeted Drugs for NSCLC
1.1 Targeted Drugs for NSCLC Market Overview
1.1.1 Targeted Drugs for NSCLC Product Scope
1.1.2 Market Status and Outlook
1.2 Global Targeted Drugs for NSCLC Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Targeted Drugs for NSCLC Market Size by Region (2015-2026)
1.4 Global Targeted Drugs for NSCLC Historic Market Size by Region (2015-2020)
1.5 Global Targeted Drugs for NSCLC Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Targeted Drugs for NSCLC Market Size YoY Growth (2015-2026)
1.6.1 North America Targeted Drugs for NSCLC Market Size YoY Growth (2015-2026)
1.6.2 Europe Targeted Drugs for NSCLC Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Targeted Drugs for NSCLC Market Size YoY Growth (2015-2026)
1.6.4 Latin America Targeted Drugs for NSCLC Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Targeted Drugs for NSCLC Market Size YoY Growth (2015-2026) 2 Targeted Drugs for NSCLC Market Overview by Type
2.1 Global Targeted Drugs for NSCLC Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Targeted Drugs for NSCLC Historic Market Size by Type (2015-2020)
2.3 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2021-2026)
2.4 Target EGFR
2.5 Target ALK
2.6 Target HER2
2.7 Target ROS1
2.8 Target BRAF
2.9 Target MEK
2.10 Target VEGFR2
2.11 Target VEGF
2.12 Target MET 3 Targeted Drugs for NSCLC Market Overview by Application
3.1 Global Targeted Drugs for NSCLC Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Targeted Drugs for NSCLC Historic Market Size by Application (2015-2020)
3.3 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2021-2026)
3.4 Squamous Cell Carcinoma of NSCLC
3.5 Adenocarcinoma of NSCLC
3.6 Large Cell Carcinoma of NSCLC 4 Global Targeted Drugs for NSCLC Competition Analysis by Players
4.1 Global Targeted Drugs for NSCLC Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for NSCLC as of 2019)
4.3 Date of Key Manufacturers Enter into Targeted Drugs for NSCLC Market
4.4 Global Top Players Targeted Drugs for NSCLC Headquarters and Area Served
4.5 Key Players Targeted Drugs for NSCLC Product Solution and Service
4.6 Competitive Status
4.6.1 Targeted Drugs for NSCLC Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data
5.1 Allergan
5.1.1 Allergan Profile
5.1.2 Allergan Main Business
5.1.3 Allergan Targeted Drugs for NSCLC Products, Services and Solutions
5.1.4 Allergan Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.1.5 Allergan Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Targeted Drugs for NSCLC Products, Services and Solutions
5.2.4 Amgen Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.2.5 Amgen Recent Developments
5.3 ARIAD Pharmaceuticals (Takeda)
5.5.1 ARIAD Pharmaceuticals (Takeda) Profile
5.3.2 ARIAD Pharmaceuticals (Takeda) Main Business
5.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Products, Services and Solutions
5.3.4 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.3.5 Beacon Pharma Limited Recent Developments
5.4 Beacon Pharma Limited
5.4.1 Beacon Pharma Limited Profile
5.4.2 Beacon Pharma Limited Main Business
5.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Products, Services and Solutions
5.4.4 Beacon Pharma Limited Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.4.5 Beacon Pharma Limited Recent Developments
5.5 BeiGene
5.5.1 BeiGene Profile
5.5.2 BeiGene Main Business
5.5.3 BeiGene Targeted Drugs for NSCLC Products, Services and Solutions
5.5.4 BeiGene Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.5.5 BeiGene Recent Developments
5.6 Biocon
5.6.1 Biocon Profile
5.6.2 Biocon Main Business
5.6.3 Biocon Targeted Drugs for NSCLC Products, Services and Solutions
5.6.4 Biocon Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.6.5 Biocon Recent Developments
5.7 Boehringer-Ingelheim
5.7.1 Boehringer-Ingelheim Profile
5.7.2 Boehringer-Ingelheim Main Business
5.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Products, Services and Solutions
5.7.4 Boehringer-Ingelheim Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.7.5 Boehringer-Ingelheim Recent Developments
5.8 Celgene Corporation
5.8.1 Celgene Corporation Profile
5.8.2 Celgene Corporation Main Business
5.8.3 Celgene Corporation Targeted Drugs for NSCLC Products, Services and Solutions
5.8.4 Celgene Corporation Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.8.5 Celgene Corporation Recent Developments
5.9 Drug International Limted
5.9.1 Drug International Limted Profile
5.9.2 Drug International Limted Main Business
5.9.3 Drug International Limted Targeted Drugs for NSCLC Products, Services and Solutions
5.9.4 Drug International Limted Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.9.5 Drug International Limted Recent Developments
5.10 Fujifilm Kyowa Kirin Biologics
5.10.1 Fujifilm Kyowa Kirin Biologics Profile
5.10.2 Fujifilm Kyowa Kirin Biologics Main Business
5.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Products, Services and Solutions
5.10.4 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.10.5 Fujifilm Kyowa Kirin Biologics Recent Developments
5.11 Genvio Pharma Limited
5.11.1 Genvio Pharma Limited Profile
5.11.2 Genvio Pharma Limited Main Business
5.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Products, Services and Solutions
5.11.4 Genvio Pharma Limited Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.11.5 Genvio Pharma Limited Recent Developments
5.12 Hetero Drugs
5.12.1 Hetero Drugs Profile
5.12.2 Hetero Drugs Main Business
5.12.3 Hetero Drugs Targeted Drugs for NSCLC Products, Services and Solutions
5.12.4 Hetero Drugs Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.12.5 Hetero Drugs Recent Developments
5.13 ImClone Systems ‎(Eli Lilly)
5.13.1 ImClone Systems ‎(Eli Lilly) Profile
5.13.2 ImClone Systems ‎(Eli Lilly) Main Business
5.13.3 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Products, Services and Solutions
5.13.4 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.13.5 ImClone Systems ‎(Eli Lilly) Recent Developments
5.14 Incepta Pharmaceuticals
5.14.1 Incepta Pharmaceuticals Profile
5.14.2 Incepta Pharmaceuticals Main Business
5.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Products, Services and Solutions
5.14.4 Incepta Pharmaceuticals Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.14.5 Incepta Pharmaceuticals Recent Developments
5.15 Mylan
5.15.1 Mylan Profile
5.15.2 Mylan Main Business
5.15.3 Mylan Targeted Drugs for NSCLC Products, Services and Solutions
5.15.4 Mylan Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.15.5 Mylan Recent Developments
5.16 Novartis
5.16.1 Novartis Profile
5.16.2 Novartis Main Business
5.16.3 Novartis Targeted Drugs for NSCLC Products, Services and Solutions
5.16.4 Novartis Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.16.5 Novartis Recent Developments
5.17 Pfizer
5.17.1 Pfizer Profile
5.17.2 Pfizer Main Business
5.17.3 Pfizer Targeted Drugs for NSCLC Products, Services and Solutions
5.17.4 Pfizer Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.17.5 Pfizer Recent Developments
5.18 Reliance Lifesciences
5.18.1 Reliance Lifesciences Profile
5.18.2 Reliance Lifesciences Main Business
5.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Products, Services and Solutions
5.18.4 Reliance Lifesciences Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.18.5 Reliance Lifesciences Recent Developments
5.19 Roche
5.19.1 Roche Profile
5.19.2 Roche Main Business
5.19.3 Roche Targeted Drugs for NSCLC Products, Services and Solutions
5.19.4 Roche Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.19.5 Roche Recent Developments
5.20 AstraZeneca
5.20.1 AstraZeneca Profile
5.20.2 AstraZeneca Main Business
5.20.3 AstraZeneca Targeted Drugs for NSCLC Products, Services and Solutions
5.20.4 AstraZeneca Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.20.5 AstraZeneca Recent Developments
5.21 Cipla
5.21.1 Cipla Profile
5.21.2 Cipla Main Business
5.21.3 Cipla Targeted Drugs for NSCLC Products, Services and Solutions
5.21.4 Cipla Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.21.5 Cipla Recent Developments
5.22 Teva
5.22.1 Teva Profile
5.22.2 Teva Main Business
5.22.3 Teva Targeted Drugs for NSCLC Products, Services and Solutions
5.22.4 Teva Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.22.5 Teva Recent Developments
5.23 OSI Pharmaceuticals
5.23.1 OSI Pharmaceuticals Profile
5.23.2 OSI Pharmaceuticals Main Business
5.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Products, Services and Solutions
5.23.4 OSI Pharmaceuticals Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.23.5 OSI Pharmaceuticals Recent Developments
5.24 Glenmark Pharmaceuticals
5.24.1 Glenmark Pharmaceuticals Profile
5.24.2 Glenmark Pharmaceuticals Main Business
5.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Products, Services and Solutions
5.24.4 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.24.5 Glenmark Pharmaceuticals Recent Developments
5.25 Natco Pharma
5.25.1 Natco Pharma Profile
5.25.2 Natco Pharma Main Business
5.25.3 Natco Pharma Targeted Drugs for NSCLC Products, Services and Solutions
5.25.4 Natco Pharma Targeted Drugs for NSCLC Revenue (US$ Million) & (2015-2020)
5.25.5 Natco Pharma Recent Developments 6 North America
6.1 North America Targeted Drugs for NSCLC Market Size by Country
6.2 United States
6.3 Canada 7 Europe
7.1 Europe Targeted Drugs for NSCLC Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe 8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific 9 Latin America
9.1 Latin America Targeted Drugs for NSCLC Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America 10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa 11 Targeted Drugs for NSCLC Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.”